USANA Health Sciences, Inc. is a publicly traded company specializing in nutritional, personal care, and weight-management products. The firm operates under four main segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The company’s notable brands include Procosa and MagneCal D. The CEO and other insiders have been selling shares in the company, with 24,632 shares of company stock valued at $1,490,529 sold by insiders in the last quarter. The company has been the subject of research analyst reports, with DA Davidson raising their target price on USANA Health Sciences from $49.00 to $52.50 and giving the company a “neutral” rating in a research note on February 13th. StockNews.com also raised USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research report on March 10th. Stay up-to-date with the latest news and analysts’ ratings for USANA Health Sciences and other related companies by signing up for MarketBeat.com’s free daily email newsletter.
Assenagon Asset Management S.A. has recently decreased its holdings in USANA Health Sciences, Inc. by 2.7% in the fourth quarter, according to their latest filing with the Securities and Exchange Commission. Other institutional investors have also made moves with their USNA shares recently. For instance, Bank of Montreal Can increased their holdings by 27.1% in the first quarter and now owns 4,327 shares of the company’s stock valued at $348,000 after buying an additional 922 shares during the period. Additionally, MetLife Investment Management LLC has increased its holdings in the company by 56.6% in the first quarter, and now owns 7,088 shares of the company’s stock valued at $563,000 after buying an additional 2,561 shares during the period.
Moreover, Rhumbline Advisers has also increased their holdings by 8.0% in the first quarter and now owns 31,182 shares of the company’s stock valued at $2,477,000 after buying an additional 2,297 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of USANA Health Sciences by 14.1% in the first quarter and now owns 10,067 shares of the company’s stock valued at $800,000 after purchasing an additional 1,241 shares during the period. Finally, Dimensional Fund Advisors LP has increased its stake in the company by 0.4% in the first quarter and now owns 566,420 shares of the company’s stock valued at $45,002,000 after purchasing an additional 2,390 shares during the period. Currently, 52.62% of the stock is owned by hedge funds and other institutional investors.
The USNA stock opened at $61.36 on Monday and has a twelve month low of $48.61 and a twelve month high of $83.78. The company has a market capitalization of $1.18 billion, a PE ratio of 17.09, and a beta of 0.74. Moreover, the business has a 50-day moving average of $59.99 and a 200-day moving average of $56.98.
In terms of recent earnings, USANA Health Sciences posted $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.31. During the same period last year, the business reported $1.03 EPS. The business had revenue of $227.96 million during the quarter, and USANA Health Sciences had a return on equity of 16.92% and a net margin of 6.94%. Research analysts expect that USANA Health Sciences, Inc. will post 2.85 earnings per share for the current fiscal year.
Insiders Sell USANA Health Sciences Shares
USANA Health Sciences insiders have been selling their shares in the company. CEO Kevin Guest sold 5,297 shares of USANA Health Sciences stock for a total value of $318,614.55 on March 7th. The chief executive officer now owns 4,058 shares of the company’s stock, valued at approximately $244,088.70. Additionally, insider Joshua Foukas sold 3,771 shares of USANA Health Sciences stock for a total value of $230,068.71 on February 16th. The insider now directly owns 3,012 shares of the company’s stock, valued at approximately $183,762.12. In the last quarter, insiders sold 24,632 shares of company stock valued at $1,490,529.
Analyst Reports on USANA Health Sciences
USANA Health Sciences has been the subject of several research analyst reports. DA Davidson raised their target price on USANA Health Sciences from $49.00 to $52.50 and gave the company a “neutral” rating in a research note on February 13th. StockNews.com also raised USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research report on March 10th.
About USANA Health Sciences
USANA Health Sciences, Inc. (NYSE:USNA) is a publicly traded company that specializes in the manufacturing and selling of nutritional supplements, personal care, and healthy food products. The company is headquartered in Salt Lake City, Utah, and has operations in more than 20 countries worldwide.
USANA Health Sciences: Developing Nutritional and Personal Care Products
USANA Health Sciences, Inc is a company that specializes in developing and manufacturing nutritional, personal care, and weight-management products. The firm operates under four main segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. Some of the company’s notable brands include Procosa and MagneCal D. USANA Health Sciences was founded by Myron W.
Receive Daily News & Ratings for USANA Health Sciences
Stay up-to-date with the latest news and analysts’ ratings for USANA Health Sciences and other related companies by signing up for MarketBeat.com’s FREE daily email newsletter.
Don’t miss interesting posts on Famousbio
